Skip to main content

CORRECTION article

Front. Oncol., 07 August 2023
Sec. Gynecological Oncology
Volume 13 - 2023 | https://doi.org/10.3389/fonc.2023.1232476

Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma

This article is a correction to:

  1. Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma

    1. Read original article
Domenica Lorusso,*Domenica Lorusso1,2*Romano DanesiRomano Danesi3Laura Deborah Locati,Laura Deborah Locati4,5Gianluca Masi,Gianluca Masi6,7Ugo De GiorgiUgo De Giorgi8Angiolo GadducciAngiolo Gadducci9Sandro PignataSandro Pignata10Roberto SabbatiniRoberto Sabbatini10Antonella SavareseAntonella Savarese11Giorgio ValabregaGiorgio Valabrega12Claudio ZamagniClaudio Zamagni13Nicoletta Colombo,Nicoletta Colombo14,15
  • 1Department of Clinical Research Planning, Fondazione Policlinico Universitario A Gemelli Istituto di Ricerca e Cura a carattere scientifico (IRCCS), Rome, Italy
  • 2Department of Life Science and Public Health, Catholic University of Sacred Heart, Rome, Italy
  • 3Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
  • 4Translational Oncology Unit, Istituto di Ricerca e Cura a carattere scientifico (IRCCS) Istituti Clinici Scientifici (ICS) Maugeri, Pavia, Italy
  • 5Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy
  • 6Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
  • 7Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
  • 8Department of Medical Oncology, Istituto di Ricerca e Cura a carattere scientifico (IRCCS) Istituto Romagnolo per lo Studio dei Tumori (IRST), Dino Amadori, Meldola, Italy
  • 9Department of Clinical and Experimental Medicine, Division of Gynecology and Obstetrics, University of Pisa, Pisa, Italy
  • 10Department of Urology and Gynecology, Istituto Nazionale Tumori Istituto di Ricerca e Cura a carattere scientifico (IRCCS) “Fondazione Giovanni Pascale”, Naples, Italy
  • 11Division of Medical Oncology 1, Istituto di Ricerca e Cura a carattere scientifico (IRCCS) -Regina Elena National Cancer Institute, Rome, Italy
  • 12University of Torino-Struttura Complessa a Direzione Universitaria (S.C.D.U.) Oncologia Azienda Ospedaliera (A.O) Ordine Mauriziano-Ospedale Umberto I, Torino, Italy
  • 13Addarii Medical Oncology, Istituto di Ricerca e Cura a carattere scientifico (IRCCS) Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
  • 14School of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy
  • 15Department of Oncological Gynecology, European Institute of Oncology (IEO) Istituto di Ricerca e Cura a carattere scientifico (IRCCS), Milan, Italy

A corrigendum on
Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma

by Lorusso D, Danesi R, Locati LD, Masi G, De Giorgi U, Gadducci A, Pignata S, Sabbatini R, Savarese A, Valabrega G, Zamagni C and Colombo N (2022)  12:979519. doi: 10.3389/fonc.2022.979519

In the published article, there was an error in Figure 1 as published. By mistake, we added the reference 18 for this figure. The corrected Figure 1 and its caption appear below.

In the published article, an author name was incorrectly written as Sabbatini Roberto. The correct name is Roberto Sabbatini.

The authors apologize for these errors and state that these do not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

FIGURE 1
www.frontiersin.org

Figure 1 Post hoc analysis of time to first onset of selected adverse reactions. Reproduced with permission from [19].

Keywords: lenvatinib, pembrolizumab, endometrial cancer, tyrosine kinase inhibitor, immune response

Citation: Lorusso D, Danesi R, Locati LD, Masi G, De Giorgi U, Gadducci A, Pignata S, Sabbatini R, Savarese A, Valabrega G, Zamagni C and Colombo N (2023) Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma. Front. Oncol. 13:1232476. doi: 10.3389/fonc.2023.1232476

Received: 31 May 2023; Accepted: 05 July 2023;
Published: 07 August 2023.

Edited and Reviewed by:

Sophia George, University of Miami, United States

Copyright © 2023 Lorusso, Danesi, Locati, Masi, De Giorgi, Gadducci, Pignata, Sabbatini, Savarese, Valabrega, Zamagni and Colombo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Domenica Lorusso, domenica.lorusso@policlinicogemelli.it

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.